farnesylthiosalicylic acid,
S-farnesylthiosalicylic acid,
S-trans,trans-farnesylthiosalicylic acid,
salirasib,
Salirasib,
162520-00-5,
Farnesylthiosalicylic acid,
S-Farnesylthiosalicylic acid,
UNII-MZH0OM550M,
FTS,
MZH0OM550M,
CHEMBL23293,
Farnesyl Thiosalicylic Acid,
2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid,
2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid,
2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid,
2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid,
Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-,
Salirasib [USAN],
Salirasib [USAN:INN],
Farnesylthiosalicyclic acid,
AK186909,
Farnesylthiosalicylate,
trans,trans Farnesyl Thiosalicylic Acid,
S-trans,trans-farnesylthiosalicylic acid,
Salirasib (INN/USAN),
Lopac-F-8175,
AC1NV5Y3,
Lopac0_000517,
MLS006010835,
GTPL6281,
Salirasib, >=98% (HPLC),
WUILNKCFCLNXOK-CFBAGHHKSA-N,
BCP27978,
EX-A1170,
ONO-7056,
trans,trans-Farnesylthiobenzoic acid,
ZINC1650377,
2030AH,
BDBM50034278,
KD-032,
MFCD00467723,
NSC685986,
s7684,
AKOS024458453,
CCG-204607,
CS-0681,
DB12681,
NSC-685986,
NCGC00015448-01,
NCGC00015448-02,
NCGC00015448-03,
NCGC00093912-01,
NCGC00093912-02,
BC600693,
HY-14754,
SMR004701762,
LS-186975,
LS-187617,
EU-0100517,
D08995,
F 8175,
W-5109,
Farnesylthiosalicylic acid, >98% (HPLC), solid,
SR-01000075885,
J-009946,
SR-01000075885-1,
2-[(3,7,11-Trimethyl-2,6,10-dodecatrienyl)thio]benzoic acid,
(E,E)-2-[(3,7,11-Trimethyl-2,6,10-dodecatrienyl)thio]benzoic Acid,
2-((2E,6E)-3,7,11-Trimethyl-dodeca-2,6,10-trienylsulfanyl)-benzoic acid,
Benzoic acid, 2-[[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl]thio]-,
166445-40-5,
S-trans,
FTS, Thyreos,
Ras antagonists, Thyreos,
D00KTV,
D05YQY,
Trans-farnesylthiosalicylicacid,
FTS (oral, cancer), Concordia,
C22H30O2S,
Th-101,
KD032,
Ras-inhibitors (cancer), Concordia,
FTS (oral, cancer), Concordia/Ono,
C22-H30-O2-S,
CID5469318,
A3787,
C093323,
Farnesylthiosalicyclic acid (oral, cancer), Concordia,